Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: A survey of the Japanese society for pediatric inflammatory bowel disease

Digestion

Volumn 77, Issue 3-4, 2008, Pages 150-154

  Tajiri, Hitoshi ^a   Tomomasa, Tsuyoshi ^b   Yoden, Atsushi ^c   Konno, Mutsuko ^d   Sasaki, Mika ^e   Maisawa, Shuniti ^f   Sumazaki, Ryo ^g   Shimizu, Toshikazu ^h   Toyoda, Shigeru ⁱ   Etani, Yuri ^j   Nakacho, Mariko ^k   Ushijima, Kosuke ^l   Kobayashi, Akio ^m  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f Morioka Children's Hospital   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Kanagawa Prefectural Shiomidai Hospital   (Japan)

^j OSAKA UNIVERSITY   (Japan)

^k RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^l KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^m SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

more..

Author keywords

6 Mercaptopurine; Activity score; Azathioprine; Corticosteroid; Leukopenia; Myelosuppression

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; PREDNISOLONE;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HEALTH SURVEY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; PANCREATITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ALGORITHMS; AZATHIOPRINE; CHILD; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; LEUKOPENIA; MALE; PREDNISOLONE; RETROSPECTIVE STUDIES;

EID: 50149122617     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140974     Document Type: Article

References (20)

1. Tomomasa T, Kobayashi A, Ushijima K, et al: Guidelines for treatment of ulcerative colitis in children. Pediatr Int 2004;46:494-496.
2. Escher JC, Taminiau JA, Nieuwenhuis EE, et al: Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58.
3. Rufo PA, Bousvaros A: Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302.
4. Seo M, Okada M, Yao T, et al: An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-976.
5. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-821.
6. Kader HA, Mascarenhas MR, Piccoli DA, et al: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-58.
7. Markowitz J, Rosa J, Grancher K, et al: Longterm 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-1351.
8. Verhave M, Winter HS, Grand RJ: Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809-814.
9. Markowitz JF: Summary of the workshop on 6-mercaptopurine/azathioprine pharmacology. Inflamm Bowel Dis 1998;4:117-118.
10. Connell WR, Kamm MA, Ritchie JK, et al: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-1085.
11. Wright S, Sanders DS, Lobo AJ, et al: Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-1128.
12. Markowitz J, Grancher K, Mandel F, et al: Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993;88:44-48.
13. Schwab M, Schaffeler E, Marx C, et al: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429-436.
14. Ansari A, Hassan C, Duley J, et al: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-1750.
15. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-146.
16. Lennard L, Gibson BE, Nicole T, et al: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-579.
17. Collie-Duguid ES, Pritchard SC, Powrie RH, et al: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
18. Kumagai K, Hiyama K, Ishioka S, et al: Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11:275-278.
19. Sumi S, Marinaki AM, Arenas M, et al: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360-367.
20. Cao H, Hegele RA: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet 2002;47:620-622.